Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 150

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 2
Chunk 150
---
 net losses in each year. Our net losses were $34.4 million and $59.9 million for the three months ended March 31, 2025 and March 31, 2024, respectively. As of March 31, 2025, we had an accumulated deficit of $1.5 billion and cash and cash equivalents and marketable securities totaling $426.9 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term. 

Comparison of the Three Months Ended March 31, 2025 and 2024

Revenue

Three Months EndedMarch 31,Change(dollars in thousands)20252024$%InstrumentsChromium$5,913 $7,850 $(1,937)(25)%Spatial8,902 17,603 (8,701)(49)Total instruments revenue14,815 25,453 (10,638)(42)ConsumablesChromium84,109 83,927 182 0 Spatial31,247 26,408 4,839 18 Total consumables revenue115,356 110,335 5,021 5 Services7,652 5,217 2,435 47 Products and services revenue$137,823 $141,005 (3,182)(2)License and royalty revenue17,060 1 17,059 NMTotal revenue$154,883 $141,006 $13,877 10 %

Products and services revenue decreased $3.2 million, or 2%, to $137.8 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. Instruments revenue decreased $10.6 million, or 42%, to $14.8 million 

19

Table of Contents

for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. Consumables revenue increased $5.0 million, or 5%, to $115.4 million for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. Services revenue increased $2.4 million, or 47%, for the three months ended March 31, 2025 as compared to three months ended March 31, 2024, primarily driven by an increase